Rubens⚡️

Hematologist & transplant physician | Interested in CAR-T therapies

[Rubens⚡️ @IsRubens]

Honored to present our work on frailty in CAR-T. Grateful to @QueraltSalas for pioneering this field and to the Clínic CAR-T team. #CART #Hematology
#EBMT2026

[Rubens⚡️ @IsRubens]

The key question is no longer efficacy. It's whether Tafa-Len-R-CHOP becomes the new standard for high-risk patients.

[Rubens⚡️ @IsRubens]

#ASCO2026 Is R-CHOP finally vulnerable? 🧵

[Rubens⚡️ @IsRubens]

3-year PFS: 67.3% vs 60.7%. One of the strongest positive phase III signals seen in years in aggressive B-cell lymphoma.

[Rubens⚡️ @IsRubens]

Buen espacio de actualización en el Foro Nacional de Expertos en Trasplante.
Interesantes discusiones sobre trasplante hematopoyético, terapias celulares y los retos reales de implementación en México.
Siempre se aprende escuchando experiencia de otros centros.

[nidia zapata @zapata_nidia]

https://t.co/zyEms4hBU8

[Rubens⚡️ @IsRubens]

Frenchie, tú no carnal 😭

[Benlazar S M A @smbenlazar]

TECLISTAMAB PLUS DARATUMUMAB (TEC-DARA) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF MAJESTEC-3 BASED ON CYTOGENETIC AND FUNCTIONAL RISK https://t.co/MCb33znS4i #mmsm #EHA26

[YO_ID @YO_ID_0722]

Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients

@CIDJournal

https://t.co/rbmMJj8fDT

[Rubens⚡️ @IsRubens]

Esto cambia la conversación:
Ya no es “¿funciona CAR-T?”
Es
👉 “¿quién tiene derecho a recibirla?”

[Benlazar S M A @smbenlazar]

CAR-T in resource-limited regions https://t.co/oUBIyY6E8O

[Rubens⚡️ @IsRubens]

8/ The real question is no longer:
“Does CAR-T work?”
It’s:
👉 Who gets access?

[Rubens⚡️ @IsRubens]

CAR-T changed hematology.
But here’s the uncomfortable truth:
👉 In much of the world, it simply doesn’t exist.
Thread 🧵

[Rubens⚡️ @IsRubens]

7/ 🔥 CAR-T isn’t limited by biology.
It’s limited by
👉 economics
👉 policy
👉 infrastructure

[Mostafa Faisal @MostafaFaisal14]

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma | Bone Marrow Transplantation https://t.co/gbS5gdMSJQ